Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922

被引:19
|
作者
Kuehnel, Annett [1 ,2 ]
Schilling, Daniela [1 ,2 ]
Combs, Stephanie E. [1 ,2 ,3 ]
Haller, Bernhard [4 ]
Schwab, Melissa [5 ]
Multhoff, Gabriele [1 ,5 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiat Oncol, Ismaninger Str 22, D-81675 Munich, Germany
[2] Helmholtz Zentrum Munchen, DRS, IRM, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[3] DKTK, Partner Site Munich, D-81675 Munich, Germany
[4] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Informat Stat & Epidemiol, Ismaningerstr 21, D-81675 Munich, Germany
[5] Tech Univ Munchen TranslaTUM, Klinikum Rechts Isar, Ctr Translat Canc Res, Einsteinstr 25, D-81675 Munich, Germany
关键词
heat shock factor (HSF-1) knockdown; heat shock proteins 70 and 27; radiosensitization; Hsp90 inhibitor NVP-AUY922; homologous recombination (HR); HEAT-SHOCK PROTEINS; SENSITIZING TUMOR-CELLS; DNA-DAMAGE RESPONSE; IN-VITRO; CHAPERONE INHIBITORS; RADIATION RESPONSE; FACTOR-1; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; EXPRESSION;
D O I
10.3390/cells8101166
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The inhibition of heat shock protein 90 (Hsp90) a molecular chaperone for multiple oncogenic client proteins is considered as a promising approach to overcome radioresistance. Since most Hsp90 inhibitors activate HSF-1 that induces the transcription of cytoprotective and tumor-promoting stress proteins such as Hsp70 and Hsp27, a combined approach consisting of HSF-1 knockdown (k.d.) and Hsp90 inhibition was investigated. A specific HSF-1 k.d. was achieved in H1339 lung cancer cells using RNAi-Ready pSIRENRetroQ vectors with puromycin resistance. The Hsp90 inhibitor NVP-AUY922 was evaluated at low concentrations-ranging from 1-10 nM-in control and HSF-1 k.d. cells. Protein expression (i.e., Hsp27/Hsp70, HSF-1, pHSF-1, Akt, beta-actin) and transcriptional activity was assessed by western blot analysis and luciferase assays and radiosensitivity was measured by proliferation, apoptosis (Annexin V, active caspase 3), clonogenic cell survival, alkaline comet, gamma H2AX, 53BP1, and Rad51 foci assays. The k.d. of HSF-1 resulted in a significant reduction of basal and NVP-AUY922-induced Hsp70/Hsp27 expression levels. A combined approach consisting of HSF-1 k.d. and low concentrations of the Hsp90 inhibitor NVP-AUY922 reduces the Hsp90 client protein Akt and potentiates radiosensitization, which involves an impaired homologous recombination mediated by Rad51. Our findings are key for clinical applications of Hsp90 inhibitors with respect to adverse hepatotoxic effects.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Activity of new heat shock protein 90 (hsp90) inhibitor NVP-AUY922 against myeloma cells sensitive and resistant to conventional agents
    McMillin, Douglas W.
    Negri, Joseph
    Delmore, Jake
    Hayden, Patrick
    Ooi, Melissa
    Mitsiades, Nicholas
    Schlossman', Robert
    Richardson, Paul G.
    Munshi, Nikhil C.
    Jensen, Michael R.
    Quadt, Cornelia
    Chene, Patrick
    Schoepfer, Joseph
    Garcia-Echeverria, Carlos
    Anderson, Kenneth C.
    Mitsiades, Constantine S.
    BLOOD, 2007, 110 (11) : 474A - 474A
  • [42] Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity
    Niewidok, Natalia
    Wack, Linda-Jacqueline
    Schiessl, Sarah
    Stingl, Lavinia
    Katzer, Astrid
    Polat, Buelent
    Sukhorukov, Vladimir L.
    Flentje, Michael
    Djuzenova, Cholpon S.
    TRANSLATIONAL ONCOLOGY, 2012, 5 (05): : 356 - U145
  • [43] Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
    Hashida, Shinsuke
    Yamamoto, Hiromasa
    Shien, Kazuhiko
    Ohtsuka, Tomoaki
    Suzawa, Ken
    Maki, Yuho
    Furukawa, Masashi
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    Kanazawa, Susumu
    Toyooka, Shinichi
    ONCOLOGY REPORTS, 2015, 33 (03) : 1499 - 1504
  • [44] Pharmakokinetic/phamacodynamic relationship of the HSP90 inhibitor NVP-AUY922 in human xenografts and patients in a clinical Phase I trial
    Jensen, Michael
    Ide, Susan
    Brueggen, Josef
    Schoepfer, Joseph
    Wang, Xiaofeng
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    CANCER RESEARCH, 2009, 69
  • [45] Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
    Kaiser, Martin
    Lamottke, Britta
    Mieth, Maren
    Jensen, Michael R.
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    Atadja, Peter
    Heider, Ulrike
    von Metzler, Ivana
    Tuerkmen, Seval
    Sezer, Orhan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (04) : 337 - 344
  • [46] The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage
    Zaidi, Shane
    McLaughlin, Martin
    Bhide, Shreerang A.
    Eccles, Suzanne A.
    Workman, Paul
    Nutting, Christopher M.
    Huddart, Robert A.
    Harrington, Kevin J.
    PLOS ONE, 2012, 7 (04):
  • [47] NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts
    Eccles, Suzanne A.
    Sharp, Swee Y.
    Raynaud, Florence I.
    Valenti, Melanie
    Patterson, Lisa
    Gowan, Sharon
    Boxall, Kathy
    Aherne, Wynne
    Rowlands, Martin
    Hayes, Angela
    Martins, Vanessa
    Urban, Federique
    Prodromou, Chrisostomos
    Pearl, Laurence
    James, Karen
    Matthews, Thomas P.
    Cheung, Kwai-Ming
    Kalusa, Andrew
    Jones, Keith
    McDonald, Edward
    Brough, Paul A.
    Massey, Andrew
    Dymock, Brian
    Drysdale, Martin
    Workman, Paul
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3522S - 3523S
  • [48] A Low Membrane Hsp70 Expression in Tumor Cells With Impaired Lactate Metabolism Mediates Radiosensitization by NVP-AUY922
    Schwab, Melissa
    Multhoff, Gabriele
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Effect of Hsp90 inhibitor NVP-AUY922 with radiation on lung adenocarcinoma cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
    Maki, Yuho
    Hashida, Shinsuke
    Yamamoto, Hiromasa
    Shien, Kazuhiko
    Ohtsuka, Tomoaki
    Suzawa, Ken
    Furukawa, Masashi
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    Kanazawa, Susumu
    Toyooka, Shinichi
    CANCER RESEARCH, 2015, 75
  • [50] Identification of predictors of response to NVP-AUY922, an HSP90 inhibitor, in an in vitro panel of human non-small-cell lung cancer (NSCLC) cell lines
    Garon, Edward B.
    Finn, Richard S.
    Dering, Judy
    Ginther, Charles
    Adhami, Shariar
    Pitts, Sharon
    Kamranpour, Naeimeh
    Hosmer, Wylie
    Jensen, Rugaard Michael
    Quadt, Cornelia
    Slamon, Dennnis J.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S599 - S599